Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$17.9M Sell
138,683
-6,774
-5% -$819K 0.68% 46
2023
Q4
$16.6M Sell
145,457
-11,358
-7% -$1.13M 0.69% 52
2023
Q3
$14.3M Buy
156,815
+4,621
+3% +$477K 0.66% 53
2023
Q2
$17.1M Sell
152,194
-7,398
-5% -$782K 0.78% 48
2023
Q1
$16.7M Sell
159,592
-59,786
-27% -$6.24M 0.8% 46
2022
Q4
$24.3M Sell
219,378
-2,152
-1% -$226K 1.09% 34
2022
Q3
$19.4M Sell
221,530
-48,787
-18% -$4.43M 0.92% 40
2022
Q2
$21.1M Sell
270,317
-6,796
-2% -$561K 0.93% 40
2022
Q1
$23.6M Buy
277,113
+6,178
+2% +$592K 0.83% 43
2021
Q4
$32.5M Sell
270,935
-2,253
-0.8% -$280K 1.05% 33
2021
Q3
$33.8M Buy
273,188
+359
+0.1% +$46.2K 1.27% 25
2021
Q2
$32.7M Sell
272,829
-5,654
-2% -$646K 1.23% 27
2021
Q1
$29.3M Buy
278,483
+4,264
+2% +$432K 1.2% 30
2020
Q4
$27.9M Sell
274,219
-20,250
-7% -$1.9M 1.32% 31
2020
Q3
$24.8M Sell
294,469
-3,183
-1% -$248K 1.28% 31
2020
Q2
$22M Sell
297,652
-10,538
-3% -$696K 1.15% 33
2020
Q1
$20.1M Buy
308,190
+109,933
+55% +$8.66M 1.38% 25
2019
Q4
$15.6M Sell
198,257
-73
-0% -$5.68K 0.83% 44
2019
Q3
$15.8M Buy
198,330
+322
+0.2% +$25.3K 0.92% 40
2019
Q2
$16.6M Buy
198,008
+4,081
+2% +$325K 0.96% 39
2019
Q1
$15.3M Buy
193,927
+8,252
+4% +$602K 0.92% 41
2018
Q4
$12.4M Buy
185,675
+574
+0.3% +$39.7K 0.85% 43
2018
Q3
$14.8M Buy
185,101
+269
+0.1% +$20.1K 0.85% 43
2018
Q2
$12.5M Sell
184,832
-611
-0.3% -$44.4K 0.77% 46
2018
Q1
$14.3M Buy
185,443
+6,960
+4% +$515K 0.91% 41
2017
Q4
$12.2M Buy
178,483
+5,301
+3% +$352K 0.77% 44
2017
Q3
$10.8M Buy
173,182
+12,122
+8% +$725K 0.73% 46
2017
Q2
$8.93M Buy
161,060
+7,178
+5% +$374K 0.62% 54
2017
Q1
$7.73M Buy
153,882
+59,921
+64% +$2.92M 0.51% 63
2016
Q4
$4.65M Buy
93,961
+5,618
+6% +$285K 0.33% 78
2016
Q3
$4.63M Buy
88,343
+10,138
+13% +$497K 0.34% 79
2016
Q2
$3.49M Buy
78,205
+7,010
+10% +$305K 0.27% 82
2016
Q1
$2.91M Buy
71,195
+60,350
+556% +$2.22M 0.24% 84
2015
Q4
$396K Buy
+10,845
New +$392K 0.03% 159

Other funds holding XYL

Cambridge Trust's XYL Position: Q1 2024 in Review

Cambridge Trust reduced its Xylem (XYL) stake by 4.7% in Q1 2024, selling an estimated $819K and leaving 138,683 shares worth $17.9M. The position accounts for 0.68% of the portfolio, ranked #46.

Cambridge Trust first reported a position in XYL in Q4 2015 and has held it in 34 quarters since. The position peaked at $33.8M in Q3 2021. 987 funds tracked by Wall St. Rank hold XYL as of Q1 2024.

  • Cambridge Trust held 138,683 shares of Xylem worth $17.9M as of Q1 2024.
  • Cambridge Trust sold 6,774 Xylem shares in Q1 2024, an estimated $819K.
  • Xylem made up 0.68% of Cambridge Trust's portfolio in Q1 2024, its #46 holding.
  • Cambridge Trust first reported a position in Xylem in Q4 2015 and has held it in 34 quarters since.
  • Cambridge Trust's Xylem position peaked at $33.8M in Q3 2021.
  • 987 funds tracked by Wall St. Rank held Xylem as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.